25/09/2007 - Roche’s latest takeover bid extension has been brushed off by histopathology diagnostics expert Ventana as it believes ‘it is worth significantly more’ than the current $3bn (€2.1bn) offer.The hostile takeover bid was initiated by Roche at the end of June to enable the company to further its ability to personalise its anticancer portfolio by supplying diagnostic tests to predict patient response.
